微芯生物(688321.SH)：CS08399片获得药物临床试验批准通知书_老虎社区_美港股上老虎

微芯生物(688321.SH)：CS08399片获得药物临床试验批准通知书

智通财经03-13

智通财经APP讯，微芯生物(688321.SH)发布公告，公司全资子公司成都微芯药业有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司产品CS08399片开展临床试验。适应症：拟用于治疗甲硫基腺苷磷酸化酶(MTAP)缺失的实体瘤和淋巴瘤。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2619116793?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-13 16:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619116793","market":"sh","top_or_hot":-1,"title":"微芯生物(688321.SH)：CS08399片获得药物临床试验批准通知书","media":"智通财经","content":"<div>\n<p>智通财经APP讯，微芯生物(688321.SH)发布公告，公司全资子公司成都微芯药业有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司产品CS08399片开展临床试验。适应症：拟用于治疗甲硫基腺苷磷酸化酶(MTAP)缺失的实体瘤和淋巴瘤。</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1413614.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>微芯生物(688321.SH)：CS08399片获得药物临床试验批准通知书</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n微芯生物(688321.SH)：CS08399片获得药物临床试验批准通知书\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-13 16:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1413614.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，微芯生物(688321.SH)发布公告，公司全资子公司成都微芯药业有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司产品CS08399片开展临床试验。适应症：拟用于治疗甲硫基腺苷磷酸化酶(MTAP)缺失的实体瘤和淋巴瘤。</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1413614.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1413614.html","article_id":"2619116793","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619116793","pubTimestamp":1773391703,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，微芯生物(688321.SH)发布公告，公司全资子公司成都微芯药业有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司产品CS08399片开展临床试验。适应症：拟用于治疗甲硫基腺苷磷酸化酶(MTAP)缺失的实体瘤和淋巴瘤。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688321":"微芯生物","BK0239":"医药制造"},"translate_title":"Microchip Biologics (688321.SH): CS08399 tablets obtained drug clinical trial approval notice","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688321":1.5},"content_text":"智通财经APP讯，微芯生物(688321.SH)发布公告，公司全资子公司成都微芯药业有限公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意公司产品CS08399片开展临床试验。适应症：拟用于治疗甲硫基腺苷磷酸化酶(MTAP)缺失的实体瘤和淋巴瘤。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}